
HCAT Stock Forecast & Price Target
HCAT Analyst Ratings
Bulls say
Health Catalyst is in the early stages of a business transformation that is expected to deliver profitable growth in the future. The recent earnings report showed a beat on revenue and EBITDA, but guidance for FY26 was slightly below consensus estimates and there is anticipated churn in DOS-related ARR. However, Health Catalyst has a strong track record of customer retention and valuable assets, making it a promising investment opportunity with a target price of $2, based on a 6.5x multiple of projected 2026 adjusted EBITDA of $33.5 million.
Bears say
Health Catalyst is facing significant challenges in terms of retaining and acquiring customers, as evidenced by a downward revision of their revenue estimates for both FY26 and FY27. This is due to a combination of factors including pressure on healthcare providers' budgets, lower margins on new professional services contracts, and competition from home-grown solutions and larger technology companies. While their strategic and operational review may potentially lead to divestitures or a sale of the company, the current uncertainty surrounding leadership and financial performance make it difficult to recommend investing in this stock.
This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.
HCAT Analyst Forecast & Price Prediction
Start investing in HCAT
Order type
Buy in
Order amount
Est. shares
0 shares